Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505355 | 1.00 | MEN1 (0.32) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL20014064 | 0.71 | MAPK1 (0.33) | LMNA | |
| SCHEMBL7099395 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL13946305 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL13809215 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL17893334 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL7103950 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL426068 | 0.68 | LMNA (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL16347736 | 0.67 | ALDH1A1 (0.47) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL5987624 | 0.67 | ALDH1A1 (0.47) | MEN1ALDH1A1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070059-B1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | NOVARTIS AG (CH) | 2002-09-25 | — | — | EP | claimed |
| US-6346626-B1 | DRUGS FOR TREATMENT OF SKIN DISORDERS SUCH AS ACNE, SEBORRHEA, ANDROGENIC ALOPECIA AND HIRSUTISM, OR IN THE TOPICAL TREATMENT OF SQUAMOUS CELL CARCINOMA | NOVARTIS AG (CH) | 2002-02-12 | — | — | US | claimed |
| EP-1070059-A1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | Novartis AG (CH) | 2001-01-24 | — | — | EP | claimed |
| WO-1999052890-A1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | NOVARTIS AG (CH) | 1999-10-21 | — | — | WO | claimed |
| EP-1070059-B1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | NOVARTIS AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| EP-1070059-B1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | NOVARTIS AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6346626-B1 | DRUGS FOR TREATMENT OF SKIN DISORDERS SUCH AS ACNE, SEBORRHEA, ANDROGENIC ALOPECIA AND HIRSUTISM, OR IN THE TOPICAL TREATMENT OF SQUAMOUS CELL CARCINOMA | NOVARTIS AG (CH) | 2002-02-12 | — | — | US | disclosed |
| US-6346626-B1 | DRUGS FOR TREATMENT OF SKIN DISORDERS SUCH AS ACNE, SEBORRHEA, ANDROGENIC ALOPECIA AND HIRSUTISM, OR IN THE TOPICAL TREATMENT OF SQUAMOUS CELL CARCINOMA | NOVARTIS AG (CH) | 2002-02-12 | — | — | US | disclosed |
| EP-1070059-A1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | Novartis AG (CH) | 2001-01-24 | — | — | EP | disclosed |
| EP-1070059-A1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | Novartis AG (CH) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052890-A1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | NOVARTIS AG (CH) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999052890-A1 | CHROMANONE AND THIOCHROMANONE DERIVATIVES | NOVARTIS AG (CH) | 1999-10-21 | — | — | WO | disclosed |